Hepatitis C virus is a major public health problem causing significant morbidity and mortality. Until recently, the standard treatment with peginterferon and ribavirin was far from being perfect due to its cost, poor tolerability and low sustained virological rates (SVR) 
Introduction
Chronic hepatitis C is a common disease that progresses slowly to cirrhosis and eventually may lead to hepatocellular carcinoma 1-3. It is a serious global medical problem that affects up to 170 million people worldwide, with over 350,000 patients dying each year from its associated liver diseases 4. Egypt is even more specifically confronted with hepatitis C virus (HCV) disease burden and has the highest prevalence of (HCV) in the world, estimated nationally at 14.7% 5.
No doubt, that the optimal outcome in chronic hepatitis C treatment is the elimination of the virus. Simply this could not be achieved with the once considered, the mainstay therapy for chronic hepatitis C (CHC) patients of peginterferon and ribavirin. This regimen remained unsatisfactory in many patients as it is not only was associated with considerable expense, adverse effects, but also required up to 48 weeks of treatment with only 40-60% success rates 6-
8.
Therefore, the urging need for more efficacious and well-tolerated regimens has led to a rapid change in hepatitis C treatment. In 2011, the addition of the recently approved novel directacting antiviral agents (DAAs) telaprevir or boceprevir to pegylated interferon-alfa and ribavirin has dramatically improved sustained virologic response (SVR) rates; however, issues such as adverse reactions, frequent dosing, and drug interactions continued to make treatment challenging 9,10.
Thus, the true revolutionary event in hepatitis C treatment was the development of sofosbuvir in 2014, which is a direct-acting nucleotide polymerase inhibitor. Many of the optimal treatment requirements were satisfied by its high efficacy, short treatment course, well tolerability and the lack of drug-drug interactions 4,11.
Several early studies with sofosbuvir either combined with ribavirin or daclatasvir (an inhibitor of NS5A) have shown an outstanding sustained virological rates (SVR) of 100% 12. However, even with the fact that sofosbuvir represents a very promising option in chronic hepatitis C treatment, providing the first "interferon free" and ribavirin free treatment, with 80-90% cure rates and with almost no side effects, its use is still limited by issues such as drug resistance and high cost. The twelve-weeks therapy with Sofosbuvir cost about 80.000 US$ 13. Therefore, In addition, UDCA has been used widely in the present clinical environment for several liver diseases and has shown to improve clinical and biochemical indices in a variety of biliary and liver diseases 25. It is now considered as the first-line treatment for patients with chronic cholestatic liver diseases, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and intrahepatic cholestasis of pregnancy (ICP) 26. However, despite the lack of its antiviral effect in CHC patients, it seems beneficial in reducing serum hepatic markers, disease activity or cirrhosis in patients unsuitable to IFN treatment 27.
The aim of this study was to evaluate and compare the hepatoprotective effect of silymarin (420 mg/day), ursodeoxycholic acid (500 mg/day), and a combined therapy of both in patients with chronic hepatitis C.
Material and Method
Initially hundred patients with CHC were collected from hepatology clinic at Beni-Suef university teaching hospital. Only 40 CHC patients (32 males and 8 females) with ages ranged from 23 to 70 years old completed the study. Patients were tested positive for HCV-RNA or
The demographic and baseline clinical characteristics of each group of patients enrolled in the study are shown in Table 1 . The severity of liver disease was graded according to the Child-Pugh score using the modification of the score as proposed by Pugh et al presented in Table 5 28. Patients were categorized into three Child-Pugh classes A, B, and C before and after therapy according to Pugh's criteria Score A (5 or 6), B (7-9), or C (10-15). Only two patients showed a change in their classes, one in group A (changed from class B to C), and one in group C (changed from class B to A).
The patients' clinical data including; splenomegally, hepatomegally and ascites showed no significant change during the study period with all treatment groups.
Medicine Science 2014;3(4):1655-74
Effect of silymarin and UDCA in HCV patients 
Patients' symptoms and examination
The most frequent symptoms during the follow up examination were nausea, vomiting, heartburn, fatigue and weight loss, however, all of these improved during 12 weeks of treatment.
In addition, the patients' physical examination showed a decrease in the complaints of jaundice, dark urine and pallor with all study regimens.
Adverse events
A grading scale for reporting adverse events were computed according to the NCI Common Terminology Criteria for adverse events v 4.0 (CTCAE) [29] and were illustrated in Table 6 .
The mean  SD of patients that showed a negative response, mild, and moderate side effects There were no differences in the types, frequencies of side effects, and patients reported no complications across the treatment period, which indicates that the study drugs were well tolerated.
Discussion
Chronic hepatitis C is a major cause of liver related morbidity and mortality. Its prevalence has increased significantly in several countries 30 and now resulted in a growing incidence of HCV-related hepatocellular carcinomas 31,32. In addition, ursodeoxycholic acid (UDCA) has been known to be an effective medical therapy for most patients with primary biliary cirrhosis (PBC) and chronic liver diseases 35,36.
However, its exact mechanism of action in delaying fibrosis is yet to be established. Though, it has been suggested that it has cytoprotective, anti-apoptotic, membrane stabilizing, antioxidative and immunomodulatory effects 37,38.
Several clinical trials have consistently shown UDCA benefits in improving the biochemical parameters 39,40, slowing down the progression of cirrhosis and even reducing the need for orthotopic liver transplantation (OLT) in primary biliary cirrhosis 41,42. Furthermore, UDCA significantly reduced serum bilirubin levels, as well as serum aminotransferases, gammaglutamyl transpeptidase and alkaline phosphatase levels in patients with alcoholic liver cirrhosis.
However, in CHC patients, despite its therapeutic benefits in biochemical improvement of serum transaminases, it failed to improve either the virological response rate or histological features of the disease 43,44. However, UDCA potential therapeutic benefits in different liver diseases still need further investigation
The current study investigated changes in serum hepatic markers, symptomatic improvement and tolerability of CHC patients induced by 12 weeks treatment of 420mg/day silymarin, 500mg/day UDCA, combined therapy of both, and placebo.
The results of this study indicated that despite silymarin significantly improved the symptoms and hence the patients' quality of life during the 12 weeks of treatment, it still failed to show any significant improvement in liver biochemistries. These results are consistent with several previous studies on silymarin that also showed its effect on improving CHC patients' wellbeing but not affecting serum hepatic markers 11,45. The different results in these studies may be attributed to different study doses of silymarin (420 mg/day), different treatment periods, the study design and/or genotypes of the patients, which may influence the results. Furthermore, many of these studies have been criticized for their low methodological quality, low patient number and even not choosing pure CHC patients. Thus, it has been agreed that there is insufficient evidence to indicate silymarin benefits in CHC patients
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48.
Regarding ursodeoxycholic acid therapy, the mean serum ALT, AST, and T bilirubin levels before and after therapy for 12 weeks were 58.6 ±21. , and 900 mg) in CHC patients and reported that 600 mg/day UDCA was the optimal dose to decrease ALT and AST levels in the those patients 47.
Regarding the combined therapy of 420 mg/day silymarin and 500 mg/day UDCA, the mean of serum levels of ALT, AST, and T bilirubin levels decreased significantly (p  0. According to Child-Pugh score classification, none of the treatment groups improved patients'
classification, which agrees with our results stating that silymarin did not cause improvement in patients with CHC.
On the other hand, despite the significant improvement in serum bilirubin levels for UDCA treated patients, Child-Pugh score classification still showed no change. This is may be due to the fact that Child-Pugh score is calculated according to five items and bilirubin is one of them.
Therefore, even if UDCA is not a first line treatment for chronic hepatitis C because its effects are not etiologically specific for this disease, practically speaking, it still can be used to supplement other chronic hepatitis therapies. Simply this is because its beneficial effects on lowering elevated serum liver parameters, which has been reported to decrease disease activity, cirrhosis, and hepatocelluar carcinoma recurrence 27,53.
However, regarding silymarin, even with its failure in improving serum liver parameters, its beneficial effects in improvement of symptoms and patients quality of life is still a point that may favour its use in CHC patients. A previous study by Schopen et al found that silymarin significantly improved liver diseases related symptoms 54. Similarly, another recent study bt El-Kamary et al suggested the safety and the potential effects of silymarin in improving symptoms of acute clinical hepatitis despite its failure on affecting biomarkers of the underlying hepatocellular inflammatory process 55.
Nevertheless, all treatment regimens in this study lacked any direct marked detectable effect regarding splenomegally, hepatomegally, and ascites, which did not change before and after therapy. This agrees with previous studies confirming the failure of either silymarin or UDCA in affecting the histological features of the disease 11,46,47. 
